What is Wedbush’s Forecast for Nuvalent FY2027 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL) – Wedbush decreased their FY2027 earnings per share estimates for Nuvalent in a report released on Wednesday, November 19th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($6.04) per share for the year, down from their previous estimate of ($5.80). Wedbush currently has a “Outperform” rating and a $125.00 price target on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Wedbush also issued estimates for Nuvalent’s FY2028 earnings at ($1.60) EPS.

NUVL has been the subject of a number of other research reports. Guggenheim increased their price objective on shares of Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. The Goldman Sachs Group upped their price target on Nuvalent from $120.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Piper Sandler increased their price target on Nuvalent from $112.00 to $128.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvalent in a research report on Wednesday, October 8th. Finally, UBS Group upped their target price on Nuvalent from $114.00 to $132.00 and gave the company a “buy” rating in a report on Friday, October 31st. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $137.86.

Nuvalent Stock Up 3.4%

Shares of NASDAQ NUVL opened at $109.53 on Monday. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of -20.59 and a beta of 1.31. Nuvalent has a 52 week low of $55.53 and a 52 week high of $112.88. The firm has a 50-day simple moving average of $91.31 and a 200-day simple moving average of $82.29.

Nuvalent (NASDAQ:NUVL) last announced its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the prior year, the business earned ($1.28) EPS.

Insider Transactions at Nuvalent

In related news, Director James E. Flynn sold 742,574 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $95.44, for a total value of $70,871,262.56. Following the completion of the transaction, the director directly owned 8,299,225 shares in the company, valued at approximately $792,078,034. This represents a 8.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Deborah Ann Miller sold 24,200 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $105.50, for a total value of $2,553,100.00. Following the sale, the insider directly owned 49,086 shares of the company’s stock, valued at approximately $5,178,573. This trade represents a 33.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,033,574 shares of company stock valued at $98,078,384 in the last ninety days. 10.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NUVL. US Bancorp DE increased its holdings in Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after purchasing an additional 188 shares during the last quarter. Kennedy Capital Management LLC boosted its position in shares of Nuvalent by 3.7% during the second quarter. Kennedy Capital Management LLC now owns 5,504 shares of the company’s stock worth $420,000 after buying an additional 196 shares during the period. Arizona State Retirement System boosted its position in shares of Nuvalent by 1.9% during the third quarter. Arizona State Retirement System now owns 11,778 shares of the company’s stock worth $1,019,000 after buying an additional 220 shares during the period. Principal Financial Group Inc. grew its stake in shares of Nuvalent by 7.7% in the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock valued at $285,000 after buying an additional 234 shares in the last quarter. Finally, Profund Advisors LLC raised its holdings in shares of Nuvalent by 2.7% in the 3rd quarter. Profund Advisors LLC now owns 10,687 shares of the company’s stock valued at $924,000 after buying an additional 279 shares during the period. Institutional investors and hedge funds own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.